Citius gets Nasdaq bid-price extension to 2027

Rhea-AI Filing Summary

Citius Pharmaceuticals, Inc. (CTXR) reports that Nasdaq has granted an extension through February 8, 2027 to regain compliance with the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Capital Market under Listing Rule 5550(a)(2), the Bid Price Rule. The company will be deemed back in compliance if its common stock closes at or above $1.00 for at least ten consecutive business days before that deadline, after which Nasdaq would send written confirmation. If Citius does not regain compliance by the deadline, Nasdaq will issue a notice that its common stock is subject to delisting, and Citius may appeal to a Nasdaq hearings panel. CTXR shares continue to trade on the Nasdaq Capital Market, and the company states it is evaluating options to regain compliance but notes there is no assurance it will do so.

Positive

• None.

Negative

• Risk of Nasdaq delisting if bid price non-compliant by February 8, 2027, which could follow if the stock does not close at or above $1.00 for at least ten consecutive business days; the company notes there is no assurance it will regain compliance.

8-K Event Classification

Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

1 item

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities

The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.

Key Figures

Extension deadline: February 8, 2027 Minimum bid price requirement: $1.00 per share Compliance measurement period: ten consecutive business days +1 more

4 metrics

Extension deadline February 8, 2027 Date through which CTXR has to evidence compliance with Nasdaq Listing Rule 5550(a)(2)

Minimum bid price requirement $1.00 per share Bid Price Rule threshold for continued inclusion on the Nasdaq Capital Market

Compliance measurement period ten consecutive business days Required period during which CTXR stock must close at or above $1.00 per share

Trading symbol CTXR Symbol under which Citius common stock trades on The Nasdaq Capital Market

Key Terms

Bid Price Rule, Nasdaq Capital Market, continued inclusion, delisting

4 terms

Bid Price Rule regulatory

"compliance with the $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”)"

Nasdaq Capital Market market

"continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2)"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

continued inclusion regulatory

"requirement for continued inclusion on the Nasdaq Capital Market"

delisting regulatory

"our common stock is subject to delisting"

Delisting occurs when a company's stock is removed from a stock exchange and is no longer available for trading there. This can happen voluntarily or because the company no longer meets the exchange's requirements. For investors, delisting means they can no longer buy or sell shares of that company on the exchange, which may make it more difficult to sell their investments or affect the stock's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Citius Pharmaceuticals (CTXR) announce about its Nasdaq listing status?

Citius Pharmaceuticals disclosed that Nasdaq granted an extension through February 8, 2027 to regain compliance with the $1.00 minimum bid price requirement for continued inclusion on the Nasdaq Capital Market under Listing Rule 5550(a)(2).

What is required for CTXR to regain compliance with Nasdaq’s Bid Price Rule?

CTXR must have its common stock close at $1.00 per share or more for at least ten consecutive business days before February 8, 2027. If achieved, Nasdaq will provide written confirmation that the company complies with the Bid Price Rule.

What happens if Citius Pharmaceuticals (CTXR) fails to meet the bid price requirement by February 8, 2027?

If CTXR does not regain compliance by February 8, 2027, Nasdaq will issue written notice that its common stock is subject to delisting. At that time, Citius may appeal the determination to a Nasdaq hearings panel.

Is Citius Pharmaceuticals’ stock still trading on Nasdaq, and under what symbol?

Citius Pharmaceuticals’ common stock continues to trade on The Nasdaq Capital Market under the symbol “CTXR”. The extension notice does not affect the current listing status at this time.

How is Citius Pharmaceuticals (CTXR) responding to the Nasdaq bid price issue?

Citius states that it is evaluating its options for regaining compliance with the Bid Price Rule and notes that there can be no assurance it will be able to regain compliance, even if it meets other listing requirements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/21/2026 - 04:16 PM Accepted by SEC EDGAR 08/21/2026 - 04:15 PM Learn about SEC filing dates

false 0001506251 0001506251 2026-08-17 2026-08-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) August 17, 2026

Citius Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Nevada

(State or other jurisdiction of incorporation)

001-38174		27-3425913
(Commission File Number)		(IRS Employer Identification No.)

11 Commerce Drive, 1st Floor,  Cranford, NJ		07016
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code (908) 967-6677

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, $0.001 par value		CTXR		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On August 17, 2026, Citius Pharmaceuticals, Inc. (the “Company”) received formal notice that the Nasdaq Stock Market LLC (“Nasdaq”) granted our request for an extension through February 8, 2027 (the “Extension Notice”) to evidence compliance with the $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). If at any time before February 8, 2027, the bid price of our common stock closes at $1.00 per share or more for a minimum of ten consecutive business days, Nasdaq will provide the Company with written confirmation of compliance with the Bid Price Rule.

If the Company does not regain compliance with the Bid Price Rule by February 8, 2027, Nasdaq will provide written notice to us that our common stock is subject to delisting. At that time, the Company may appeal the determination to a Nasdaq hearings panel.

The Extension Notice has no effect at this time on the listing of our common stock, which will continue to trade on The Nasdaq Capital Market under the symbol “CTXR”. We are currently evaluating our options for regaining compliance. There can be no assurance that we will be able to regain compliance with the Bid Price Rule, even if we maintain compliance with the other listing requirements. 

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CITIUS PHARMACEUTICALS, INC.
Date: August 21, 2026	/s/ Leonard Mazur
	Leonard Mazur
	Chairman and Chief Executive Officer

2

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 3.0 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB